WallStreetZenWallStreetZen

NASDAQ: CSBR
Champions Oncology Inc Stock

$5.14+0.28 (+5.76%)
Updated Jul 17, 2024
CSBR Price
$5.14
Fair Value Price
$1.83
Market Cap
$69.87M
52 Week Low
$4.50
52 Week High
$7.14
P/E
-7.14x
P/B
-33.95x
P/S
1.6x
PEG
N/A
Dividend Yield
N/A
Revenue
$49.22M
Earnings
-$9.73M
Gross Margin
40.1%
Operating Margin
-19.62%
Profit Margin
-19.8%
Debt to Equity
-14.02
Operating Cash Flow
-$5M
Beta
0.8
Next Earnings
Jul 22, 2024
Ex-Dividend
N/A
Next Dividend
N/A

CSBR Overview

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CSBR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CSBR ($5.14) is overvalued by 180.72% relative to our estimate of its Fair Value price of $1.83 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CSBR ($5.14) is not significantly undervalued (180.72%) relative to our estimate of its Fair Value price of $1.83 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CSBR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CSBR due diligence checks available for Premium users.

Be the first to know about important CSBR news, forecast changes, insider trades & much more!

CSBR News

Valuation

CSBR fair value

Fair Value of CSBR stock based on Discounted Cash Flow (DCF)
Price
$5.14
Fair Value
$1.83
Overvalued by
180.72%
CSBR ($5.14) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CSBR ($5.14) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CSBR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CSBR price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-7.14x
Industry
-21.17x
Market
30.24x

CSBR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-33.95x
Industry
6.35x

CSBR's financial health

Profit margin

Revenue
$12.0M
Net Income
-$2.5M
Profit Margin
-21.1%
CSBR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CSBR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$26.8M
Liabilities
$28.8M
Debt to equity
-14.02
CSBR's short-term liabilities ($21.97M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CSBR's short-term assets ($13.20M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CSBR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CSBR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$919.0k
Investing
-$126.0k
Financing
$0.0
CSBR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CSBR vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CSBR$69.87M+5.76%-7.14x-33.95x
THTX$70.58M-2.66%-14.90x-4.14x
CNTB$68.88M-1.57%-1.16x0.68x
VOR$68.05M-1.29%-0.56x0.55x
DTIL$71.96M+0.10%-1.41x1.93x

Champions Oncology Stock FAQ

What is Champions Oncology's quote symbol?

(NASDAQ: CSBR) Champions Oncology trades on the NASDAQ under the ticker symbol CSBR. Champions Oncology stock quotes can also be displayed as NASDAQ: CSBR.

If you're new to stock investing, here's how to buy Champions Oncology stock.

What is the 52 week high and low for Champions Oncology (NASDAQ: CSBR)?

(NASDAQ: CSBR) Champions Oncology's 52-week high was $7.14, and its 52-week low was $4.50. It is currently -27.96% from its 52-week high and 14.22% from its 52-week low.

How much is Champions Oncology stock worth today?

(NASDAQ: CSBR) Champions Oncology currently has 13,593,767 outstanding shares. With Champions Oncology stock trading at $5.14 per share, the total value of Champions Oncology stock (market capitalization) is $69.87M.

Champions Oncology stock was originally listed at a price of $7.20 in Feb 2, 2007. If you had invested in Champions Oncology stock at $7.20, your return over the last 17 years would have been -28.61%, for an annualized return of -1.96% (not including any dividends or dividend reinvestments).

How much is Champions Oncology's stock price per share?

(NASDAQ: CSBR) Champions Oncology stock price per share is $5.14 today (as of Jul 17, 2024).

What is Champions Oncology's Market Cap?

(NASDAQ: CSBR) Champions Oncology's market cap is $69.87M, as of Jul 18, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Champions Oncology's market cap is calculated by multiplying CSBR's current stock price of $5.14 by CSBR's total outstanding shares of 13,593,767.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.